performed a comprehensive genomic analysis in a large population of R/R AML patients carrying IDH mutations who were treated by ivosidenib, and confirmed that RTK pathway mutations are associated with primary resistance to ivosidenib. The gene discussed is IDH1; the disease is acute myeloid leukemia.